Kintara Therapeutics, Inc (KTRA)

Etorro trading 970x250
Kintara Therapeutics, Inc (KTRA) Logo

About Kintara Therapeutics, Inc

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California. Address: 12707 High Bluff Drive, San Diego, CA, United States, 92130

Kintara Therapeutics, Inc News and around…

Latest news about Kintara Therapeutics, Inc (KTRA) common stock and company :

Kintara Presents Updates on Two Phase 2 Clinical Studies at the 2021 Society for Neuro-oncology Annual Meeting
18 Nov, 2021 Yahoo! Finance

Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced data from two scientific posters for its Phase 2 clinical studies of VAL-083, the Company's lead compound for the treatment of glioblastoma multiforme (GBM). The data are being presented at the 26th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) being held in Boston on November 18-21, 2021.

KTRA: More AGILE Sites Greet New CEO
17 Nov, 2021 Yahoo! Finance

By John Vandermosten, CFA NASDAQ:KTRA READ THE FULL KTRA RESEARCH REPORT First Quarter Fiscal Year 2022 Operational and Financial Results Kintara Therapeutics, Inc. (NASDAQ:KTRA) announced first quarter fiscal year 2022 financial and operational results in a November 15 th press release and concurrently filed its 10-Q with the SEC. Highlights for the first quarter ended September 30, 2021 and

Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90+ Companies
15 Nov, 2021 FinancialContent
Kintara Therapeutics Announces Fiscal 2022 First Quarter Financial Results and Provides Corporate Update
15 Nov, 2021 Yahoo! Finance

https://www.kintara.com/ (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal first quarter ended September 30, 2021 and provided a corporate update.

Kintara Therapeutics to Present at the Q4 Investor Summit Virtual Conference on November 17, 2021
11 Nov, 2021 Yahoo! Finance

Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announces today that its Chief Executive Officer, Robert E. Hoffman, will present a corporate overview at the Q4 Investor Summit Conference, which is being held virtually on November 16 – 17, 2021.

Kintara Announces Changes to Executive Leadership Team
09 Nov, 2021 Yahoo! Finance

https://www.kintara.com/ (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that Robert E. Hoffman, the Company's Chairman, will succeed Saiid Zarrabian as President and Chief Executive Officer, effective November 8, 2021. Mr. Hoffman will continue in his capacity as the Company's Chairman, and Mr. Zarrabian will transition to heading up Kintara's strategic partnerships initiative and will remai

Hot Penny Stocks To Add to Your Watchlist Right Now
05 Nov, 2021 FinancialContent
2 “Strong Buy” Penny Stocks That Are Ready to Boom
03 Nov, 2021 Yahoo! Finance

Investors know that the key to profits is in the return – and that means, a willingness to shoulder risk. Risk is relative, of course, and tends to run hand-in-hand with the return potential. Find a stock with a giant return potential, and chances are, you’ve also found one with a higher risk profile. The highest returns usually come along with the lowest share prices. After all, when a stock is priced for just pennies, even a small gain in share price translates into a huge return. Which means

12 Health Care Stocks Moving In Thursday's Intraday Session
21 Oct, 2021 FinancialContent

Gainers Sio Gene Therapies (NASDAQ:SIOX) stock moved upwards by 22.79% to $2.64 during Thursday's regular session. ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
21 Oct, 2021 FinancialContent

Gainers Sio Gene Therapies (NASDAQ:SIOX) shares rose 13.95% to $2.45 during Thursday's pre-market session. The ...

12 Health Care Stocks Moving In Tuesday's Intraday Session
19 Oct, 2021 FinancialContent

Gainers Redhill Biopharma (NASDAQ:RDHL) stock increased by 18.27% to $5.76 during Tuesday's regular session. Redhill ...

Do These Penny Stocks Present a Buying Opportunity At Current Levels?
14 Oct, 2021 FinancialContent
KTRA: FY21 Financial Results
14 Oct, 2021 Yahoo! Finance

By John Vandermosten, CFA NASDAQ:KTRA READ THE FULL KTRA RESEARCH REPORT Fiscal Year 2021 Operational and Financial Results Kintara Therapeutics, Inc. (NASDAQ:KTRA) announced fiscal year 2021 financial and operational results in a September 29 th press release and filed its 10-K with the SEC. Highlights for the fourth quarter ended June 30, 2021 and to-date include: ➢ GCAR GBM AGILE trial launch

40 Stocks Moving In Wednesday's Mid-Day Session
13 Oct, 2021 FinancialContent

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
13 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're at the halfway point of the trading week and that has us checking in on the biggest pre-market stock movers for Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

20 Stocks Moving in Wednesday's Pre-Market Session
13 Oct, 2021 FinancialContent

Gainers Puxin Limited (NYSE: NEW) rose 52.1% to $0.6901 in pre-market trading after dipping 24% on Tuesday. Jasper Therapeutics, ...

45 Biggest Movers From Yesterday
13 Oct, 2021 FinancialContent

Gainers ESSTech Inc (NYSE: GWH) shares surged 128.4% to close at $23.80 onTuesday. ESS Inc, the Bill Gates-backed battery maker ...

Best Biotech Penny Stocks on Reddit to Buy Now? 4 For Your Watchlist
12 Oct, 2021 FinancialContent
30 Stocks Moving In Tuesday's Mid-Day Session
12 Oct, 2021 FinancialContent

Gainers ESS Tech Inc (NYSE: GWH) shares jumped 96.4% to $20.46. ESS Inc, the Bill Gates-backed battery maker went public on the ...

15 Stocks Moving in Tuesday's Pre-Market Session
12 Oct, 2021 FinancialContent

Gainers Quanterix Corporation (NASDAQ: QTRX) shares rose 17.6% to $48.55 in pre-market trading after the company announced its ...

Kintara Therapeutics to Present at the LD Micro Main Event Conference
11 Oct, 2021 Yahoo! Finance

Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announces today that its Chief Executive Officer, Saiid Zarrabian, will present a corporate overview at the 14th Annual LD Micro Main Event Conference which is being held at the Luxe Sunset Bel-Air in Los Angeles from October 12 – 14, 2021.

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
30 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Kintara Therapeutics: Q4 Earnings Insights
30 Sep, 2021 FinancialContent

Kintara Therapeutics(NASDAQ:KTRA) stock fell by 5.89% on Wednesday after the company reported its Q4 earnings results on ...

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
29 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

Kintara Therapeutics Announces Fiscal Year 2021 Financial Results and Provides Corporate Update
29 Sep, 2021 Yahoo! Finance

https://www.kintara.com/ (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal year ended June 30, 2021 and provided a corporate update.

Kintara Announces Closing of $15.0 million Offering Priced at a Premium to Market
28 Sep, 2021 Yahoo! Finance

Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing, or are resistant to, current treatment regimens today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, with several healthcare-focused institutional investors of 12,000,000 shares of its common stock (or common stock equivalents) and warrants to purchase up to an ag

Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2021
28 Sep, 2021 FinancialContent

Upgrades For Bouygues (OTC:BOUYF), Jefferies upgraded the previous rating of Hold to Buy. At the moment, the stock has a 52-week-high ...

KTRA: 2Q:21 Update
27 Sep, 2021 Yahoo! Finance

By John Vandermosten, CFA NASDAQ:KTRA READ THE FULL KTRA RESEARCH REPORT VAL-083 Phase II Topline Data (MD Anderson) - Adjuvant Arm Kintara Therapeutics, Inc. (NASDAQ:KTRA) announced topline results from its Phase II study of lead candidate, VAL-083, as adjuvant therapy in newly-diagnosed glioblastoma multiforme (GBM) patients. The last patient in this group was dosed on June 3 rd and the topline

Kintara Therapeutics, Inc (KTRA) is a NASDAQ Common Stock listed in , ,

970x250